<DOC>
	<DOCNO>NCT02958696</DOCNO>
	<brief_summary>HTL0018318 selective muscarinc M1 agonist . This study phase I , open label , randomise , crossover , single dose , trial healthy volunteer compare relative bioavailability HTL0018318 give oral aqueous solution capsule formulation .</brief_summary>
	<brief_title>Relative Bioavailability HTL0018318 Oral Aqueous Solution Versus Capsules</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Male female healthy volunteer . 2 . Aged 1855 year . 3 . A body mass index ( Quetelet index ) range 18.034 . 4 . Sufficient intelligence understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement , entire trial . 5 . Willingness comply contraception requirement trial . 6 . Willingness give write consent participate reading information consent form , opportunity discuss trial investigator delegate . 7 . Willingness give write consent data enter The Overvolunteering Prevention System . 1 . Clinically relevant abnormal history , physical finding , ECG , laboratory value pretrial screening assessment could interfere objective trial safety volunteer . 2 . QTcF outside range 300450 msec male , 300470 msec female rest ECG screen baseline . 3 . Family history unexplained sudden death , sudden death due long QT syndrome . 4 . Clinically relevant abnormal finding base 24 h ECG Holter monitor screening , include follow : &gt; 200 ventricular ectopic heart beat , ventricular tachycardia , define &gt; = 3 successive ventricular ectopic beat rate &gt; 120 bpm , second degree heart block , sustain cardiac arrhythmia , include atrial fibrillation , complete heart block supraventricular tachycardia ( SVT ) , symptomatic arrhythmia except isolated extra systole . 5 . Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , gamma glutamyl transferase ( GGT ) total bilirubin &gt; 1.5 x ULN screening , laboratory blood chemistry test result outside normal reference range unless deem clinically significant investigator . 6 . Clinically significant renal insufficiency indicate glomerular filtration rate lower agerelated L screen . In event glomerular filtration rate &gt; 80 , eligibility may confirm second measurement . 7 . Blood pressure heart rate supine position screen examination outside range 90140 mm Hg systolic , 5090 mm Hg diastolic ; heart rate 45100 beats/min . Subject borderline value include value deem clinically significant investigator . 8 . Presence acute chronic illness history chronic illness sufficient invalidate volunteer 's participation trial make unnecessarily hazardous . 9 . Impaired gastrointestinal , endocrine , thyroid , hepatic , cardiovascular , respiratory , haematological , renal neurological function , diabetes mellitus , coronary heart disease , history psychotic mental illness deem clinically significant investigator . 10 . History chronic respiratory condition , asthma , recurrent chest infection chronic obstructive pulmonary disease . 11 . History epilepsy seizure . 12 . History severe allergy . Nonactive hayfever acceptable . 13 . Surgery ( e.g . stomach bypass ) medical condition might affect absorption , metabolism elimination medicine . 14 . Presence history severe adverse reaction drug . 15 . Woman pregnant lactating , premenopausal woman sexually active use reliable method contraception . 16 . Use prescription overthecounter medicine , herbal remedy nutritional supplement , 21 day first dose trial medication end study , exception acetaminophen ( paracetamol ) , hormonal contraceptive hormone replacement therapy ( HRT ) . 17 . Presence history drug alcohol abuse last 5 year , intake 21 unit alcohol weekly ( men ) 14 unit alcohol weekly ( woman ) , use cigarette nicotinecontaining product 3 month first dose end study . 18 . Evidence drug abuse urine testing . 19 . Positive test hepatitis B , hepatitis C HIV . 20 . Positive test alcohol smoking dosing . 21 . Participation another clinical trial new chemical entity prescription medicine within previous 3 month . 22 . Loss 500 mL blood 3 month trial , eg blood donor . 23 . Possibility volunteer cooperate requirement protocol . 24 . Objection General Practitioner ( GP ) volunteer enter trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>